April 12, 2022 News by Marta Figueiredo, PhD New Blood Biomarker Technology May Help to Predict MS Activity Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…
February 23, 2022 News by Marisa Wexler, MS NfL Blood Test May Help Predict MS Activity, Treatment Response Levels of a protein called neurofilament light chain (NfL) in the blood can be used to predict the risk of future disease activity in people with multiple sclerosis (MS), according to a new study. The results also suggest that changes in NfL levels could be used to deduce the extent…
November 11, 2021 News by Marisa Wexler, MS sNfL Levels Linked to Relapse-free Disability Progression, Move to SPMS Measuring levels of the protein serum neurofilament light chain (NfL)Ā can help to identify people with relapsing-remitting multiple sclerosis (RRMS) at higher risk of relapse-free disability progression or conversion to secondary-progressive disease, according to a study from Germany. The study, “NfL predicts relapse-free progression in a longitudinal…
September 7, 2021 News by Yedida Y Bogachkov PhD Brain Atrophy, Serum NfL Levels May Predict Cognition Early in MS A blood test for serum neurofilament light chain (sNfL) levels, along with radiological findings, can help to detect early cognitive issues in people recently diagnosed with multiple sclerosis (MS), a study suggests. The study āCortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients…
September 2, 2021 News by Steve Bryson, PhD Combo of Biomarkers Predict Future Disease Activity In people with early-stage multiple sclerosis (MS), the presence of high levels of neurofilament light chain (sNfL) protein in the bloodstream combined with thinning of the retina is a strong indicator of future disease activity, a recent study demonstrates. āOur findings encourage the application of both sNfL and retinal…
February 26, 2021 News by Forest Ray PhD #ACTRIMS2021 – Blood NFL Levels Seen to Rise With Markers of MS Progression Editorās note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25ā27. GoĀ hereĀ to see all the latest stories from the conference. Higher blood levels of neurofilament light chain (sNfL) were linked with disability, brain atrophy, and other features of…
October 12, 2020 News by Sara Guariglia Metabolic Changes Relating to MS Onset, Progression Focus of Study A $957,000 grant will support research at the University at BuffaloĀ intoĀ events that precede the onset of neurodegeneration inĀ multiple sclerosis (MS). Specifically, the funding byĀ the U.S. Army Medical Research and Development CommandĀ will be used to investigate possible changes in cell metabolism that lead toĀ disease onset or progression in…
April 1, 2020 News by Forest Ray PhD Blood Levels of Nerve Cell Protein Likely Marker of Brain Injury to Come A nerve cell protein found in the blood shows potential as a biomarker of neuroinflammation and future neurodegeneration in the early stages ofĀ multiple sclerosis (MS), a study reports. The protein, called serum neurofilament light chain (sNfL), is a known marker of injury to axons (nerve…
June 19, 2019 News by Patricia Inacio, PhD Lemtrada Lowers Levels of Nerve Damage Biomarker Better Than Rebif, Trial Data Show Treatment with Sanofi GenzymeāsĀ LemtradaĀ (alemtuzumab) for up to two years lowers the levels of serum neurofilament light chain (sNfL), a proposed biomarker of nerve damage, in relapsing-remitting multiple sclerosisĀ (RRMS) patients to levels comparable to those seen in healthy people, data from the CARE-MS I study shows. Lemtradaās effectiveness…